The Silent Killer!
February 17, 2026
Not Your Grandfather’s Orphan Drug Status
February 24, 2026
Medical Patents Broker Inc. By Kenneth Pearce, President
Phase I trials are mandatory before a product reaches the market. For a new biologic or pharmaceutical, the risk of failing Phase I is often greater than the chance of success. It is a classic Catch-22: without taking the risk, there is no de-risking.
Medical Patents Broker Inc. views this conundrum as a valuation pivot point. If Phase I is successful, the value of the medical patent generally increases. Safe use in humans removes one more hurdle to the market. For a corporate buyer or licensee, this shift changes the entire math of a transaction.
The "Safety-First" Reality Phase I is primarily about demonstrating that the invention is safe for use in, on, or about humans.
- Small Cohorts, Big Stakes: These studies typically involve a small group (20–80 participants). The FDA’s primary interest is identifying adverse events and safe dosage ranges.
- The Net Present Value Shift: In biotech, perceived value enhances actual worth. An asset that has successfully cleared Phase I has a statistically higher probability of reaching the market—a milestone that can double or triple the "meeting of the minds" value of the underlying patent.
- The Buyer’s Comfort Zone: Generally, the larger the company, the less willing they are to take a risk on a out-of-house new product. Even with a cleared Phase I, the odds of enticing a massive corporation can feel like a game of blackjack. However, a mid-sized "Phase II company" looking to build its pipeline may be very interested.
The Mirror Analogy Rarely does the garage inventor of a better automotive mirror entice a major vehicle manufacturer to license or purchase the mirror directly. But when that inventor turns to a mentor, it becomes possible to secure a deal with a third-party supplier who then sells that mirror to the manufacturer.
Similarly, MPB can assist in orchestrating the medical patent to the next level. Innovation is the spark, but using the "national road" rather than the "interstate" is usually a safer and friendlier way to transfer technology.
If you are an inventor, a university, or a Phase I company, MPB can assist in engineering the marketability of your medical patent.
